News file for: Prostate Cancer
A microRNA-based test for prostate cancer could help distinguish aggressive tumors from slow growing ones and prevent unnecessary biopsies.
The androgen receptor signaling inhibitor XTANDI® has been approved for castration-resistant prostate cancer in Japan.
Researchers and clinicians in Australia are leading a clinical trial to test a GPS-like device that tracks the position of the prostate as it moves during radiotherapy.
Medifocus has entered into a joint venture agreement with Ideal Concept Group to sell and market its Prolieve treatment in China and other Asian countries.
BioChain and Epigenomics AG have announced a collaboration to bring Epigenomics’ Septin9 colorectal cancer screening technology to China.
Scientists have completed the first ever analysis of national trends in cancer incidence among the eight largest Asian American groups.
The Prostate Cancer Foundation has funded two new young Chinese investigators to lead innovative prostate cancer research projects within the country.
Two common viruses known to be associated with human cancers are both present in most prostate cancers, a new study suggests.
Innovative new technology has been used to identify and profile a novel combination of proteins that may improve treatment for prostate disorders.
The Prostate Cancer Foundation announced yesterday the launch of PCF China, a research initiative that will identify, fund, and promote innovative research projects within China.